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ABSTRACT 
Aim: The renal safety of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients 
with type 2 diabetes mellitus (T2DM) remains uncertain. This meta-analysis aimed to 
compare the effects of each SGLT2 inhibitor on adverse renal outcomes in patients with 
T2DM.  
Methods: PubMed, EMBASE, CENTRAL, and ClinicalTrials.gov were searched up to 
May 24 2016 without language or date restrictions. Randomized trials that reporting at 
least one renal-related adverse outcome in T2DM patients treated with SGLT2 inhibitors 
were included. Pairwise and network meta-analyses were carried out to calculate the 
odds ratio (OR) with 95% confidence interval (CI) and a cumulative meta-analysis was 
performed to assess the robustness of evidence.  
Results: In total, we extracted 1,334 composite renal events among 39,741 patients 
from 58 trials and 511 acute renal impairment/failure events among 36,716 patients from 
53 trials. Dapagliflozin was significantly associated with a greater risk of composite renal 
events than placebo (OR, 1.64; 95% CI, 1.26 to 2.13). Empagliflozin seemed to confer a 
lower risk than placebo (OR, 0.63, 95% CI, 0.54 to 0.72), canagliflozin (OR, 0.48; 95% CI, 
0.29 to 0.82), and dapagliflozin (OR 0.38, 95% CI, 0.28 to 0.51). With regard to acute 
renal impairment/failure, only empagliflozin was significantly associated with a lower risk 
than placebo (OR, 0.72, 95% CI, 0.60 to 0.86). Our cumulative meta-analysis indicated 
the robustness of our significant findings.  
Conclusions: Our meta-analysis indicated that dapagliflozin may increase the risk of 
adverse renal events while empagliflozin may have a protective effect among T2DM 
patients. Further data from large well-conducted RCTs and real-world setting are 
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warranted.  
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INTRODUCTION 
The sodium glucose cotransporter 2 (SGLT2) is located in the proximal tubule of the 
kidney and accounts for 90% of reabsorption of filtered glucose in the kidney[1]. SGLT2 
inhibitors with highly potent in selectively inhibiting SGLT2 [2], have been approved for 
treating type 2 diabetes mellitus (T2DM). Unlike other glucose-lowering agents, SGLT2 
inhibitors exert insulin-independent hypoglycemia effects by selectively inhibiting renal 
glucose reabsorption and thereby increasing urinary glucose excretion [3]. Many clinical 
trials have demonstrated that SGLT2 inhibitors have beneficial effects on glycemic 
control, body weight loss, and blood pressure reduction without causing hypoglycemia 
[4-6].  
Because of the mechanisms of action of SGLT2 inhibitors in the kidney, there is a 
concern that they may induce renal impairment. Intravascular volume depletion can be 
caused by osmotic diuresis in patients receiving SGLT2 inhibitors [7]. Subsequently, 
transient hypotensive episodes secondary to volume reduction are likely to result in 
acute kidney injury [8]. An early and dose-dependent increase in serum creatinine or 
blood urea nitrogen (BUN) levels and a decrease in estimated glomerular filtration rate 
(eGFR) were observed after the use of SGLT2 inhibitors, especially in patients with 
chronic kidney disease (CKD) [9, 10]. On June 14th, 2016, the U.S. Food and Drug 
Administration (FDA) strengthened an existing warning about the risk of acute kidney 
injury for canagliflozin and dapagliflozin [11]. The risk of adverse renal events was 
increased with the use of dapagliflozin or canagliflozin as compared to placebo [4, 12]. 
However, some trials showed that the early abnormal renal parameters returned toward 
baseline in patients receiving SGLT2 inhibitors over time [13]. Some evidence indicated 
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that SGLT2 inhibitors might offer renoprotection in patients with T2DM [14]. Recently, 
one large randomized trial (EMPA-REG OUTCOME trial) with up to 5 years of follow-up 
showed that patients taking empagliflozin were less likely to experience acute renal 
failure (including acute kidney injury) than those taking placebo [15].  
Regarding possible adverse effects of SGLT2 inhibitors on renal outcomes, the evidence 
from individual randomized trials has been inconsistent. We therefore conducted a 
comprehensive pairwise and network meta-analyses to synthesize both direct and 
indirect evidence from all available randomized controlled trials (RCTs) to compare the 
effects of individual SGLT2 inhibitors on adverse renal outcomes in patients with T2DM. 
We also used cumulative meta-analysis to determine when the evidence became robust.  
METHODS 
The report of this review was performed according to the PRISMA extension statement 
for reporting of systematic reviews incorporating network meta-analyses of health care 
interventions [16] . 
Search strategy  
The electronic databases of PubMed, Embase, and Cochrane Central Register of 
Controlled Trials (CENTRAL) were searched to identify eligible RCTs using relevant 
search terms described in Table S1. We identified articles published up to May 24, 2016, 
without restrictions on language, year of publication, or publication status. An additional 
manual search of the references of included trials, relevant meta-analyses, and 
ClinicalTrials.gov was carried out to identify other published and unpublished trials.  
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Study selection  
We included RCTs that compared SGLT2 inhibitors to placebo or other active 
antidiabetic treatments in adults with T2DM. We required follow-up periods of at least 12 
weeks and reporting of at least one renal-related adverse outcome (e.g., increased 
creatinine or BUN level, decreased eGFR, renal impairment, or renal failure) in published 
articles. In addition, the trials with the results presented on ClinicalTrials.gov were also 
considered. The primary outcomes included composite renal events (including increased 
creatinine or BUN level, decreased eGFR, renal impairment, and renal failure) and acute 
renal impairment/failure events reported by each investigator as an adverse event (or 
serious adverse event) using pre-specified lists from the Medical Dictionary for 
Regulatory Activities (MedDRA) or laboratory values (e.g. serum creatinine, BUN, or 
eGFR). Conference abstracts were excluded due to lack of detailed information 
assessing the trials’ characteristics, definition of outcomes, and trial quality.  
Data extraction and quality assessment  
A standardized data extraction form was developed as follows: first author (publication 
year), study characteristics (country of origin and funding), patient characteristics 
(inclusion criteria, background treatments, ethnicity, mean age, proportion of male, 
pre-existing CKD, and pre-existing cardiovascular disease), interventions (type of 
SGLT2 inhibitor and control), and renal-related adverse events (incidence of any 
specified adverse renal outcome). 
If multiple reports were retrieved on the same population, only the most complete and/or 
more recently reported data were used. If adverse renal outcomes were not reported in 
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the publication, data from the “Serious Adverse Events” section on the ClinicalTrials.gov 
were extracted. In addition, if trials with the results presented on ClinicalTrials.gov, but 
without reporting adverse renal events, the number of events was assumed to be zero. If 
two different comparison groups of non-overlapping patients (i.e., A vs. B and C vs. D) 
were included in the same report, each group was considered separately. If three arms 
(i.e., A vs. B vs. A+B) were evaluated in the trials, only two arms (A vs. B) were included. 
When placebo was switched to an active comparator in extended-period trials, only the 
period with placebo was documented. Two reviewers (HT and DL) independently 
performed study selection and data extraction, and any disagreements were resolved by 
consensus or referral to a third reviewer (YS). 
We used the Cochrane risk-of-bias tool to qualitatively assess the quality of RCTs [17]. 
Two authors (HT and DL) independently reviewed and judged each RCT as having low, 
high, or unclear risk of bias based on the following criteria: random sequence generation 
(selection bias), allocation concealment (selection bias), blinding (performance bias and 
detection bias), incomplete outcome data (attrition bias), and selective reporting 
(reporting bias).  
Statistical analysis  
Pairwise and network meta-analyses with their odds ratios (ORs) and 95% confidence 
intervals (CIs) were performed to calculate comparative effect sizes.  
For pairwise meta-analyses, ORs were calculated based on Peto’s method for direct 
comparisons between SGLT2 inhibitors and control due to low event rates [18]. An I² 
statistic was used to evaluate heterogeneity within meta-analyses, with <25%, 25%- 75%, 
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and >75% indicating low, moderate, and high level of statistical heterogeneity, 
respectively. In addition, several subgroup analyses were carried out to explore the 
source of heterogeneity: (1) type of control group (placebo vs active treatment); (2) 
length of trial duration (≤ 26 weeks vs 26-104 weeks vs ≥104 weeks); (3) age (< 60 
years vs ≥60 years); (4) pre-existing cardiovascular disease (yes vs no); and (5) 
pre-existing chronic kidney disease (yes vs no). 
For indirect and mixed comparisons, a network meta-analysis with a random-effects 
model was used to compare interventions. The network meta-analysis was performed 
with STATA version 14.0 using the “mvmeta” command and programmed STATA routines 
[19, 20]. For zero-event RCT, a 0.5 zero-cell correction was applied [21]. To rank the 
SGLT2 inhibitors for a specified outcome, we estimated the relative ranking probabilities 
of each treatment using surface under the cumulative ranking curve (SUCRA) 
probabilities and mean ranks. For adverse renal outcomes, higher SUCRA probability 
and lower mean rank indicate a safer intervention [22]. The heterogeneity variance (tau) 
estimated by a restricted maximum likelihood method was employed to quantify 
between-study heterogeneity for each outcome [23]. 
To check for possible inconsistency, a loop inconsistency–specific approach was 
introduced to evaluate the difference between direct and indirect estimates for a specific 
comparison [24]. To check the assumption of consistency in the entire network, a 
design-by-treatment interaction model using the χ2 test was applied [25]. To test the 
robustness of the findings, we assessed the modulating effects of different trial and 
participant characteristics on primary outcomes of sensitivity analyses restricted to trials 
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involving patients without CKD, white patients, SGLT2 inhibitor combination therapy, or 
excluding the largest trial (EMPA-REG OUTCOME Trial), separately. In addition, a 
cumulative pairwise meta-analysis was performed to test the stability of our significant 
findings with the accumulation of data over time [26]. Finally, a comparison-adjusted 
funnel plot was used to assess small-study effects within a network of interventions, with 
symmetry around the summary effect line indicating the absence of small-study effects 
[27].  
RESULTS 
Study selection and study characteristics 
Of 1,874 citations retrieved through electronic search and 8 eligible RCTs identified from 
ClinicalTrials.gov, finally, 58 eligible RCTs were included in this meta-analysis (Figure 1). 
The Table S2 summarized the characteristics of the 58 trials, in which a total of 38,079 
patients were randomly assigned to groups receiving either SGLT2 inhibitors 
(canagliflozin, dapagliflozin, empagliflozin, or luseogliflozin) or control treatments 
(placebo or other active anti-diabetic medications). Sample sizes of individual trials 
ranged from 71 to 7,020 participants, and the periods of follow-up ranged from 12 to 260 
weeks. One trial provided two independent datasets for two different comparisons 
(empagliflozin versus metformin and empagliflozin versus sitagliptin), which we 
considered separately [28]. Combined data from two trials were presented on 
ClinicalTrials.gov and were included as one independent trial [29, 30]. Networks of 
eligible comparisons for the primary outcomes are presented in the Figure 2, showing 
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predominantly pairwise comparisons of SGLT2 inhibitors with placebo and absence of 
pairwise comparison between any two SGLT2 inhibitors. 
Risk of bias within studies 
The risk of bias for the 58 RCTs was summarized as follows: 37 RCTs reported 
adequate random-sequence generation, 35 RCTs reported adequate allocation 
concealment; masking conditions were high in three RCTs, of which two were open-label 
in extended periods and the other set one arm with open label; and 24 RCTs reported 
events of adverse renal outcome. All of the trials were funded by industry. More 
information is presented in the Figure S1. 
Meta-analysis 
The analyses of composite renal events included data from 58 trials reporting 1,334 
events among 39,741 patients. The results of pairwise meta-analysis are presented in 
Table S3. Canagliflozin (OR, 1.69; 95%CI, 1.06 to 2.72) and dapagliflozin (OR, 1.70; 
95%CI, 1.34 to 2.16) were significantly associated with greater risk of composite renal 
events as compared with control group, respectively. Empagliflozin was significantly 
associated with lower risk of composite renal events than control group (OR, 0.62; 
95%CI, 0.54 to 0.72). Subgroup analysis by type of control showed that canagliflozin 
posed higher risk of composite renal events than other active treatments (OR, 2.57; 
95%CI, 1.10 to 6.04), dapagliflozin significantly increased the risk as compared with 
placebo (OR, 1.71; 95%CI, 1.32 to 2.21), while empagliflozin significantly decreased the 
risk as compared with placebo (OR, 0.62; 95%CI, 0.54 to 0.72). An increased risk of 
composite renal events was observed in trials with duration from 26 to 104 weeks for 
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canagliflozin (OR, 1.71; 95%CI, 1.00 to 2.92) and dapagliflozin (OR, 2.06; 95%CI, 1.56 
to 2.71), respectively, while a decreased risk for empagliflozin in those with durations 
more than 104 weeks (OR, 0.62; 95%CI, 0.53 to 0.72). It should be noted that in the 
patients without pre-existing CKD, canagliflozin and dapagliflozin were associated with 
increased risk of composite renal events, with an OR of 2.05 (95%CI, 1.17 to 3.59) and 
1.80 (95%CI, 1.40 to 2.30) respectively, while empagliflozin was associated with 
decreased risk (OR, 0.62; 95%CI, 0.53 to 0.72). Statistical heterogeneity within the 
pairwise meta-analysis was low to moderate, with an I2 statistic from 0 to 51.9%. Our 
network meta-analysis showed that dapagliflozin was significantly associated with a 
higher risk of composite renal events (OR, 1.64; 95%CI, 1.26 to 2.13), while 
empagliflozin was significantly associated with a lower risk than placebo (OR, 0.63; 
95%CI, 0.54 to 0.72). In particular, empaglilflozin was significantly associated with fewer 
events than dapagliflozin (OR, 0.38; 95%CI, 0.28 to 0.51) and canagliflozin (OR, 0.48; 
95%CI, 0.29 to 0.82) (Figure 3A). We generated hierarchies of treatment effects based 
on the SUCRA probabilities. Empagliflozin posed the lowest risk for composite renal 
events, whereas dapagliflozin conferred the highest risk among these three SGLT2 
inhibitors. The network meta-analysis had low statistical heterogeneity (tau≈0). We 
detected no inconsistency in the loop of comparisons between direct and indirect 
evidence (all 95%CIs across zero). In addition, no global inconsistency was detected 
within any network (P=0.76). Detailed information was presented in the Tables S4-S6. 
A total of 511 events of acute renal impairment/failure were reported in 53 trials with 
36,716 patients. Pairwise meta-analysis showed that canagliflozin (OR, 1.82; 95%CI, 
0.28 to 11.77) and dapagliflizin (OR, 1.93; 95%CI, 0.42 to 8.83) had a tendency to 
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increase the risk of acute renal impairment/failure events as compared with control group, 
respectively. However, empagliflozin posed a significantly lower risk of acute renal 
impairment/failure than control group (OR, 0.72; 95%CI, 0.59 to 0.87). Subgroup 
analysis by type of control showed that only empagliflozin significantly reduced the risk of 
acute renal impairment/failure as compare with either placebo (OR, 0.73; 95%CI, 0.60 to 
0.88) or active treatments (OR, 0.07; 95%CI, 0.01 to 0.74) (Table S7). Low to moderate 
evidence of statistical heterogeneity was detected, with the I2 statistic from 0 to 66.8%. 
The results from our network meta-analysis with a low level of statistical heterogeneity 
(tau≈0) showed that only empagliflozin was significantly associated with lower risk of 
acute impairment/failure events than placebo (OR, 0.72; 95%CI, 0.60 to 0.86). Neither 
canagliflozin (OR, 0.67; 95%CI, 0.25 to 1.80) nor dapagliflozin (OR, 0.75; 95%CI, 0.33 to 
1.74) was significantly associated with acute renal impairment/failure (Figure 3B). 
According to the SUCRA probabilities, empagliflozin conferred the lowest risk of acute 
renal impairment/failure, whereas dapagliflozin had the highest risk among these three 
SGLT2 inhibitors. In addition, no loop inconsistency in the loop of comparisons (all 
95%CIs across zero) or global inconsistency within any network was detected (P = 0.72). 
Detailed information was presented in the Tables S4-S6. 
Sensitivity and cumulative meta-analyses 
The main results did not appreciably change in the sensitivity analysis after being 
restricted to trials involving patients without CKD, white patients, and SGLT2 inhibitor 
combination therapy. However, the significantly protective effect of empagliflozin against 
acute renal impairment/failure seemed to be largely driven by the largest trial 
(EMPA-REG OUTCOME trial) [15]. When this trial was removed, there was no 
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significant difference between empagliflozin and placebo in risk of acute renal 
impairment/failure events (OR, 0.55; 95%CI, 0.21 to 1.42). The rankings of SGLT2 
inhibitors for adverse renal outcomes in the sensitivity analyses were relatively stable 
(Table 1).  
In addition, a cumulative meta-analysis by publication year of trials showed that 
dapagliflozin was significantly associated with a higher risk of composite renal events 
than placebo since 2014 when a trial was published by Leiter LA et al in 2014 
(cumulative OR, 1.74; 95%CI, 1.21 to 2.50) and the effect size was robust in the 
following years (Figure 4A). In consistent with the sensitivity analysis, the cumulative 
meta-analysis also showed that the significantly lower risk of acute renal 
impairment/failure from empagliflozin versus placebo was largely driven by the 
EMPA-REG OUTCOME trial (Figure 4B). Further, the comparison-adjusted funnel plot 
revealed no small-study effects, which indicated the absence of any over-estimate or 
under-estimate of the effect of SGLT2 inhibitors (Figure S2). 
DISCUSSION 
Our comprehensive meta-analysis of 58 RCTs involving 39,741 patients showed that 
dapagliflozin was consistently associated with a significantly higher risk of composite 
renal events than placebo. Conversely, empagliflozin was significantly associated with a 
lower risk of composite renal events and acute renal impairment/failure than placebo. 
However, the significance of the effect on acute renal outcomes by empagliflozin was 
largely driven by one single study, the EMPA-REG OUTCOME trial.  
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Our findings clearly show that, compared to placebo, dapagliflozin was significantly 
associated with an increased risk of composite renal events. Moreover, the cumulative 
meta-analysis showed that sufficient evidence had emerged by 2014. Some previous 
trials also reported that dapagliflozin was associated with an increased incidence of renal 
impairment or failure and creatinine increase or eGFR decrease in T2DM patients, 
especially in elderly patients or those with extant renal impairment [9, 10, 31]. Evidence 
showed that elevated serum creatinine or lowered eGFR returned to baseline levels 
more frequently in patients treated with dapagliflozin than with a comparator after a few 
months of therapy or when therapy was discontinued [32-35]. These findings indicated 
that abnormal changes in eGFR or creatinine during dapagliflozin therapy might reflect a 
temporary and reversible change in renal function, possibly caused by hemodynamic 
changes related to osmotic diuresis, reduction in blood pressure, or altered intrarenal 
hemodynamics [10, 14, 34, 36]. Our subgroup analysis found that an increased risk of 
composite renal events was observed in the studies with follow-up durations from 26 to 
104 weeks, but not in those with either less than 26 weeks or more than 104 weeks. 
Nevertheless, one pooled analysis of 12 trials showed that in patients with normal or 
mildly impaired renal function, dapagliflozin was not associated with elevated risk of 
acute renal toxicity or deterioration of renal function [34]. Our meta-analysis (7 events 
from 9391 patients) also found no sign of significantly increased risk of dapagliflozin on 
acute renal impairment/failure.  
There are suggestive evidence that renal function was reduced by other SGLT2 
inhibitors, indicating a class effect [14, 37]. Canagliflozin was associated with early 
abnormal changes in serum creatinine, BUN levels, or eGFR [14]. Our pairwise 
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meta-analysis also showed that canagliflozin was significantly associated with elevated 
risk of composite renal events, despite a nonsignificantly increased risk was observed 
from network meta-analysis. Empagliflozin also showed a similar pattern of short term 
decrease in renal function, but with a significantly improvement after the discontinuation 
of empagliflozin [38]. However, our meta-analysis showed that empagliflozin was 
associated with decreased risk of adverse renal outcomes. Furthermore, in June 2016, 
the U.S FDA strengthened an existing warning about the risk of acute kidney injury for 
canagliflozin and dapagliflozin [11]. Given some suggestive evidence of the harmful 
effects of dapagliflozin or canagliflozin on renal function, monitoring of long-term renal 
function is necessary for these two drugs in T2DM patients, especially those with renal 
impairment. 
It is interesting to find that only empagliflozin was significantly associated with lower risk 
of both composite renal events and acute renal impairment/failure events than placebo, 
suggesting its possible renoprotective effects in patients with T2DM. However, the 
precise mechanisms underlying the renal benefit of empagliflozin are still unclear. Some 
evidence showed that SGLT2 inhibitors might reduce proximal tubular hypertrophy, 
inflammation, and fibrosis, and ameliorate the hyperfiltration that accompanies 
hyperglycemia [39]. SGLT2 inhibitors might reduce albuminuria, a marker of glomerular 
damage in patients with CKD [9, 37, 40]. However, it is important to note that 
EMPA-REG OUTCOME trial contributed substantially to the summary estimate of acute 
renal impairment/failure events (about 95% weight of the summary estimate), and when 
this trial was removed, there was no significant difference between empagliflozin and 
placebo [15]. The renal benefit from empagliflozin was largely driven the EMPA-REG 
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OUTCOME trial. Further, data from well-conducted RCTs and real-world setting with 
renal events as primary outcomes are warranted to confirm our findings.   
A key issue is whether the renal benefit from empagliflozin applies to other drugs in class 
of SGLT2 inhibitors. However, our findings suggest that dapagliflozin and canagliflozin 
may have a harm effect on renal function. The disparate effects of the various SGLT2 
inhibitors on renal impairment/failure are probably due to data availability of adverse 
renal events. Adverse renal events associated with dapagliflozin were usually reported 
as adverse events in the peer-reviewed journals, while most data on the other two 
SGLT2 inhibitors were extracted from ClinicalTrials.gov, with renal events being 
considered serious adverse events. In addition, patients with chronic comorbid disease 
(e.g., coronary heart disease) might affect renal outcomes[41]. Emapagliflozin was 
associated with a significant reduction in risk of renal outcomes in EMPA-REG 
OUTCOME Trial, which included T2DM patients at high cardiovascular risk. However, 
we did not find a similar trend in other SGLT2 inhibitors. Notably, there is some evidence 
indicating pharmacokinetics or pharmacodynamics differences and variabilities in 
various SGLT2 inhibitors. The likelihood of renal-related adverse events may depend on 
whether and to what extent the drug is cleared from the body through kidney excretion 
[42]. It is reported that about 75% of dapagliflozine is eliminated by the renal pathway, 
while the other two SGLT2 inhibitors appear to be less subject to renal clearance (33% of 
canagliflozin and 54% of empagliflozin) [43-45]. Nevertheless, additional data are 
required to explore different renal effects by these SGLT2 inhibitors. Several large 
ongoing prospective RCTs including Canagliflozin and Renal Events in Diabetes with 
Estimated Nephropathy Clinical Evaluation (CREDENCE; NCT02065791), CANagliflozin 
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cardiovascular Assessment Study-renal outcomes (CANVAS-R; NCT01989754), and 
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of 
Cardiovascular Events (DECLARE-TIMI58; NCT01730534), will not only provide enough 
statistical power to determine the renal safety of SGLT2 inhibitors, but also solve the 
issue of whether or not the renal benefit is a class effect or a specific drug effect. 
In contrast to the null finding from one previous published meta-analysis [46], our 
meta-analysis showed that dapagliflozin had harmful effects on renal function, while 
empagliflozin had renoprotecive effects. Compared to that study, our meta-analysis has 
several advantages: (1) our research question was more specific on adverse renal 
outcomes; (2) this is the first network meta-analysis to comprehensively assess the 
comparative effects of SGLT2 inhibitors on adverse renal outcomes; (3) we 
systematically identified eligible RCTs that presented at least one adverse renal outcome. 
Additional data from Clinicaltrials.gov were also checked to identify unpublished studies; 
and (4) multiple sensitivity analyses and cumulative meta-analysis were performed to 
test the robustness of the findings.  
However, some limitations of our study merit consideration. First, we focused on all or 
acute adverse renal outcomes as reported by trials. The adverse renal events (including 
an increase of creatinine or BUN, or a decrease of eGFR) was defined by the 
investigators as an adverse event (or a serious adverse event), which did not allow a 
clear separation between chronic and acute renal outcomes and identifying each 
outcome. Second, majority of the trials (especially canagliflozin and empagliflozin) are 
less likely to report adverse renal outcomes in their full publications due to unknown 
reasons, although additional data were obtained from the ClinicalTrials.gov to minimize 
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the risk of reporting bias. Third, variation in background treatments and patient 
characteristics across RCTs might contribute to heterogeneity, although we found low 
statistical heterogeneity and no inconsistency in our network model. Finally, adverse 
renal outcomes for SGLT2 inhibitors other than empagliflozin and dapagliflozin remain 
uncertain due to lack of sufficient RCT data. 
In conclusion, there has been an increased risk harm effects on renal function in patients 
taking dapagliflozin while empagliflozin appeared to have renal protective effects. These 
results call for future safety monitoring of SGLT2 inhibitors in RCTs and real-world 
settings. 
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Table 1 Sensitivity analyses for the odds ratios of SGLT2 inhibitor versus placebo on adverse renal outcomes. 
  
 
Treatments Overall 
analysis 
SUCR
A rank 
Non-CKD 
patients 
SUCR
A rank 
White 
patients 
SUCR
A rank 
Exclude 
EMPA-REG 
OUTCOME 
Trial 
SUCR
A rank 
Combinatio
n therapy 
SUCRA 
rank 
Composite renal events 
Canagliflozin 1.29 
(0.78,2.15) 
4 1.44 
(0.77,2.67) 
3 1.34 
(0.80,2.24) 
3 1.27 
(0.75,2.15)  
4 1.24 
(0.73,2.09) 
4 
Dapagliflozin 1.64 
(1.26,2.13) 
5 1.76 
(1.34,2.31) 
4 1.68 
(1.29,2.20) 
4 1.60 
(1.12,2.29)  
5 1.70 
(1.30,2.23) 
5 
Empagliflozin 0.38 
(0.28,0.51) 
1 0.62 
(0.54,0.72) 
1 0.63 
(0.55,0.73) 
1 0.47 
(0.23,0.96)  
1 0.63 
(0.55,0.72) 
1 
Luseogliflozin 0.67 
(0.22,2.06) 
2 NA NA NA NA 0.67 
(0.22,2.10)  
2 0.67 
(0.22,2.06) 
2 
Active treatments 1.01 
(0.58,1.75) 
3 1.08 
(0.62,1.89) 
2 0.97 
(0.55,1.72) 
2 0.96 
(0.53,1.73)  
3 1.02 
(0.57,1.82) 
3 
Heterogeneity 
(tau)1 
≈0 
Low 
 ≈0 
Low  
 ≈0 
Low  
 =0.1 
Low 
 ≈0 
Low 
 
Acute renal impairment/failure events 
Canagliflozin 0.67 
(0.26,1.73) 
2 0.62 
(0.22,1.76) 
2 0.69 
(0.25,1.91) 
2 0.85 
(0.26,2.76) 
2 0.62 
(0.21,1.79) 
2 
Dapagliflozin 0.75 
(0.33,1.74) 
3 0.86 
(0.35,2.09) 
3 0.80 
(0.33,1.93) 
3 0.87 
(0.32,2.35) 
3 0.75 
(0.31,1.85) 
3 
Empagliflozin 0.72 
(0.60,0.86) 
1 0.72 
(0.59,0.86) 
1 0.73 
(0.61,0.88) 
1 0.55 
(0.21,1.42) 
1 0.72 
(0.60,0.87) 
1 
Active treatments 1.42 
(0.52,3.89) 
4 1.43 
(0.52,3.96) 
4 1.17 
(0.37,3.69) 
4 1.37 
(0.43,4.32) 
4 1.10 
(0.32,3.73) 
4 
Heterogeneity 
(tau)1 
≈0 
Low 
 ≈0 
Low 
 ≈0 
Low 
 ≈0 
Low 
 ≈0 
Low 
 
1 Degree of between-study heterogeneity. NA, not applicable; CKD, chronic kidney disease; SUCRA, surface under the cumulative ranking curve.  
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Table S1 Search Strategy 
Search data: May-24, 2016 
Data source  Search terms 
PubMed #1 Sodium glucose co-transporter  
#2 SGLT2 OR SGLT-2 OR SGLT 2 
#3 Tofogliflozin OR Apleway OR Deberza OR CSG452 
#4 Empagliflozin OR Jardiance 
#5 dapagliflozin OR Farxiga OR Forxiga 
#6 Canagliflozin OR Invokana 
#7 Sotagliflozin OR LX4211 
#8 luseogliflozin OR Lusefi 
#9 Ipragliflozin OR Suglat 
#10 remogliflozin OR BHV091009 
#11 sergliflozin OR GW869682X 
#12 ertugliflozin OR MK-8835 OR PF-04971729 
#13 OR#1- #12 
#14 random*   
#15 "Randomized Controlled Trial"[Publication Type]  
#16 RCT or RCTs 
#17 #14 OR #16 
#18 #13 AND #17 
CENTRAL TITLE-ABSTRACT- KEYWORDS（Sodium Glucose co-transporter OR SGLT2 OR 
SGLT-2 OR SGLT 2 OR  Tofogliflozin OR Empagliflozin OR dapagliflozin OR 
Canagliflozin OR Sotagliflozin OR luseogliflozin OR Ipragliflozin OR remogliflozin OR 
sergliflozin OR ertugliflozin） 
Embase (TITLE-ABSTRACT-INDEX TERM (Sodium Glucose co-transporter OR SGLT2 OR 
SGLT-2 OR SGLT 2 OR Tofogliflozin OR Empagliflozin OR dapagliflozin OR 
Canagliflozin OR Sotagliflozin OR luseogliflozin OR Ipragliflozin OR remogliflozin OR 
sergliflozin OR ertugliflozin) 
AND TITLE-ABSTRACT-INDEX TERM (RCT* OR random*))  
ClinicalTrials.gov Tofogliflozin OR Empagliflozin OR dapagliflozin OR Canagliflozin OR Sotagliflozin OR 
luseogliflozin OR Ipragliflozin OR remogliflozin OR sergliflozin OR ertugliflozin 
 
 
 
3 
 
Table S2 Characteristics of included Studies  
Author 
 (year) 
NCT N Interventions Background 
therapy 
Mean 
Age 
(year) 
 Male 
(%) 
Race 
(Prim
ary) 
Pre-
existi
ng 
CKD  
Pre-
existing 
CVD   
Outcomes reported Data source 
of outcome 
Follow-up 
(weeks) 
Leiter  LA 
(2015)[1] 
NCT00968812 1450 Canagliflozin 
vs glimepiride 
MET 56.2 52.0 White No No GFR decreased and renal 
failure (leading to 
discontinuation) 
Publications 104 
Stenlof K 
(2013)[2] 
NCT01081834 584 Canagliflozin 
vs placebo 
Naïve 
treatment 
55.4 44.2 White No  No Acute renal failure based on 
prespecified SAE item from 
MedDRA  
Clinitrial trial 
registration 
26 
Yale JF 
(2014)[3] 
NCT01064414 269 Canagliflozin 
vs placebo 
SU or INS 68.5 60.6 White Yes No Decreased renal function (e.g. 
specific terms of renal 
impairment and blood 
creatinine 
increased) 
Publications 52 
Wilding 
JPH 
(2013)[4] 
NCT01106625 469 Canagliflozin 
vs placebo 
MET + SU 56.8 51.0 White No No Not reported3 Clinitrial trial 
registration 
52 
Bode B 
(2015)[5] 
NCT01106651 714 Canagliflozin 
vs placebo 
OAD 63.6 55.5 White No No Renal impairment Clinitrial trial 
registration 
104 
Forst T 
(2014)[6] 
NCT01106690 342 Canagliflozin 
vs placebo 
MET+PIOG 57.4 63.2 White No No Not reported3 Clinitrial trial 
registration 
26 
Inagaki  N 
(2015)[7] 
NCT01413204 272 Canagliflozin 
vs placebo 
Naïve 
treatment 
58 70.5 Asian No No Not reported3 Clinitrial trial 
registration 
24 
Rosenstock 
J (2016)[8] 
NCT01809327 1186 Canagliflozin 
vs placebo 
MET 54.9 48.0 White No No Renal-related AEs (e.g. blood 
Cr increased, GFR decreased, 
and renal impairment) based 
on AE reports, and safety 
laboratory tests. 
Publications 30 
Neal B 
(2015)[9] 
NCT01032629 1972 Canagliflozin 
vs placebo 
INS+OAD 62.7 66.0 White No No Renal-related adverse events 
based on prespecified AE 
items from MedDRA 
Publications 52 
Qiu R 
(2014)[10] 
NCT01340664 279 Canagliflozin 
vs placebo 
MET 57.4 46.6 White No No GFR decreased (lead ing to 
discontinuation ) based on AE 
reports, and safety laboratory 
tests 
Publications 18 
NCT013819
00 
(2014)[11] 
NCT01381900 676 Canagliflozin 
vs placebo 
MET+SU 56.3 53.6 Asian No No Not reported3 Clinitrial trial 
registration 
18 
Rosenstock 
J (2012)[12] 
NCT00642278 451 Canagliflozin 
vs placebo 
MET 52.9 52.0 White No No Not reported3 Clinitrial trial 
registration 
12 
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Inagaki  
N(2013)[13] 
NCT01022112 383 Canagliflozin 
vs placebo 
Naïve 
treatment 
57.4 68.1 Asian No No Not reported3 Clinitrial trial 
registration 
12 
Schernthan
er G 
(2013)[14] 
NCT01137812 755 Canagliflozin 
vs sita  
MET+SU 56.7 55.9 White No No Not reported3 Clinitrial trial 
registration 
52 
Lavalle-
González  
FJ(2013)[15
] 
NCT01106677 1284 Canagliflozin 
vs sita vs 
placebo 
MET 55.4 47.1 White No No Not reported3 Clinitrial trial 
registration 
26 
Henry RR 
(2012)[16] 
NCT00859898 638 Dapagliflozin 
+ MET vs 
Dapagliflozin 
vs MET 
Naïve 
treatment 
51.6 48.2 White No No Not reported3 Clinitrial trial 
registration 
24 
Rosenstock 
J (2015)[17] 
NCT01606007 534 Dapagliflozin 
+ SAXA vs 
SAXA vs 
Dapagliflozin 
MET 54 50.2 White No No GFR decrease based on 
laboratory values 
Publications 24 
Nauck  MA 
(2011)[18] 
NCT00660907 814 Dapagliflozin 
vs glipizide 
MET 58 55.3 White No No Renal impairment/failure (e.g. 
calculated Cr renal clearance 
decreased, renal impairment, 
blood Cr increased, eGFR,and 
acute renal failure) based on  
prespecified AE item from 
MedDRA and laboratory 
values 
Publications 52 
Cefalu WT 
(2015)[19] 
NCT01031680 922 Dapagliflozin 
vs placebo 
OAD 62.9 68.3 White No Yes Renal impairment/failure (e.g. 
decreased renal Cr clearance, 
renal impairment, acute renal 
failure, increased blood Cr, 
decreased GFR) based on 
prespecified  renal 
impairment/failure AE items 
from MedDRA  
Publications 52 
Leiter  LA 
(2014)[20] 
NCT01042977 962 Dapagliflozin 
vs placebo 
Standard 
care 
63.8 66.9 White No Yes Renal impairment/failure (e.g. 
renal impairment, renal failure, 
and acute renal failure) based 
on prespecified AE item from 
MedDRA  
Publications 52 
Bailey CJ 
(2012)[21] 
NCT00736879 282 Dapagliflozin 
vs placebo 
Naïve 
treatment 
53 50.0 White No No Not reported3 Clinitrial trial 
registration 
24 
Bailey CJ 
(2013)[22] 
NCT00528879 546 Dapagliflozin 
vs placebo 
MET 53.9 53.5 White No No Renal impairment/failure (e.g. 
increases in serum Cr >1.5 
timesthe baseline value or 
attaining an absolute value of 
221 umol/l)  (defined by a 
prespecified list) 
Publications 102 
Strojek K 
(2011)[23] 
NCT00680745 592 Dapagliflozin 
vs placebo 
Glimepiride 59.8 48.1 White No No Renal impairment/failure 
based on prespecified AE item 
from MedDRA and laboratory 
Publications 24 
5 
 
values 
Wilding JP 
(2014)[24] 
NCT00673231 807 Dapagliflozin 
vs placebo 
INS ± OAD 59.3 47.8 White No No Renal impairment/failure 
based on prespecified AE item 
from MedDRA and laboratory 
values 
Publications 104 
Kaku  K 
(2014)[25] 
NCT01294423 261 Dapagliflozin 
vs placebo 
Naïve 
treatment 
58.9 59.4 Japa
n 
Yes No Renal impairment based on 
laboratory values, calculated 
Cr clearance, and eGFR 
Publications 24 
Jabbour SA 
(2014)[26] 
NCT00984867 447 Dapagliflozin 
vs placebo 
SIT ±MET 54.9 54.8 White No No Renal impairment (e.g., 
decreased renal Cr clearance) 
Publications 48 
Bolinder J 
(2014)[27] 
NCT00855166 180 Dapagliflozin 
vs placebo 
MET 60.7 55.6 White No No Renal impairment/failure  
based on prespecified AE 
items from MedDRA 
Publications 104 
Matthaei  S 
(2015)[28] 
NCT01392677 216 Dapagliflozin 
vs placebo 
MET+SU 61 49.1 White No No renal impairment/failure (e.g. 
renal Cr clearance) based on 
prespecified AE items from 
MedDRA 
Publications 52 
Mathieu C 
(2015)[29] 
NCT01646320 320 Dapagliflozin 
vs placebo 
SAXA+MET 55.1 45.6 White No No GFR decreased Publications 52 
Kohan DE 
(2014)[30] 
NCT00663260 252 Dapagliflozin 
vs placebo 
Standard 
care 
67 65.1 White Yes No Renal impairment or failure 
based on adverse event or 
laboratory 
abnormalities 
Publications 104 
Schumm-
Draeger PM 
(2015)[31] 
NCT01217892 399 Dapagliflozin 
vs placebo 
MET 58.5 44.9 White No No Renal impairment/failure- 
based on prespecified AE item 
from MedDRA  
Publications 16 
Ji LN 
(2014)[32] 
NCT01095653 393 Dapagliflozin 
vs placebo 
Naïve 
treatment 
51.4 64.9 Asian No No Renal impairment based on 
prespecified AE item from 
MedDRA  
Publications 24 
Weber M 
(2016)[33] 
NCT01195662 449 Dapagliflozin 
vs placebo 
OAD 56.5 55.0 White No No Renal function  based on 
prespecified AE item from 
MedDRA  
Publications 12 
Yang WY 
(2015)[34] 
NCT01095666 444 Dapagliflozin 
vs placebo 
MET 53.8 80.3 Asian No No AE related to renal function 
based on prespecified AE item 
from MedDRA  
Publications  24 
Winding JP 
(2009)[35] 
NCT00357370 71 Dapagliflozin 
vs placebo 
INS+OAD 56.7 59.1 White No No Renal failure based on 
treatment- 
emergent adverse events, vital 
signs, and laboratory 
measurements 
Publications 12 
NCT011374
74 
(2014)[36] 
NCT01137474 944 Dapagliflozin 
vs placebo 
OAD ± INS NR 56.0 White No No Not reported3 Clinitrial trial 
registration 
12 
NCT009722
44 
(2013)[37] 
NCT00972244 279 Dapagliflozin 
vs placebo 
Naïve 
treatment 
57.3 57.3 Asian No No Not reported3 Clinitrial trial 
registration 
12 
6 
 
Araki E 
(2016)[38] 
NCT02157298 182 Dapagliflozin 
vs placebo 
INS±DPP4I 58 70.9 Asian No No GFR decreased  based on 
prespecified AE item from 
MedDRA  
Publications 16 
Lewin A 
(2015); & 
DeFronzo 
RA 
(2015)[39, 
40]1 
NCT01422876 1341 Empagliflozin 
+ LINA vs 
Empagliflozin 
vs LINA 
 ±MET 55.4 53.8 White No No Acute renal failue based on 
prespecified SAE item from 
MedDRA  
Clinitrial trial 
registration 
52 
Ridderstrale 
M 
(2014)[41] 
NCT01167881 1545 Empagliflozin 
vs glimepiride 
MET 55.9 55.2 White No No Renal failure, acute renal 
failure based on prespecified 
SAE item from MedDRA  
Clinitrial trial 
registration 
104 
Ferrannini  
E (2013)-
Study1[42] 
2 
NCT00881530 271 Empagliflozin 
vs metformin 
Naïve 
treatment 
57.9 49.4 White No No Not reported3 Clinitrial trial 
registration 
90 
Ferrannini  
E (2013)-
Study2[42] 2 
NCT00881530 388 Empagliflozin 
vs SIT 
MET 58.9 51.5 White No No Not reported3 Clinitrial trial 
registration 
90 
Araki E 
(2015)[43] 
NCT01368081 336 Empagliflozin 
vs metformin 
SU 61.3 72.0 NR No No Not reported3 Clinitrial trial 
registration 
52 
NCT007890
35 
(2014)[44] 
NCT00789035 406 Empagliflozin 
vs metformin 
vs placebo 
Naïve 
treatment 
57.5 52.0 NR No No Not reported3 Clinitrial trial 
registration 
12 
Barnett AH 
(2014)[45] 
NCT01164501 741 Empagliflozin 
vs placebo 
OAD 62.6 61.0 White Yes No Renal impairment/failure (e.g . 
acute renal failure) based on 
prespecified SAE item from 
MedDRA  
Clinitrial trial 
registration 
52 
Haring HU 
(2013)[46] 
NCT01159600
/ 
NCT01289990 
669 Empagliflozin 
vs placebo 
MET+SU 57.1 51.0 Asian No No Not reported3 Clinitrial trial 
registration 
76 
Haring HU 
(2014)[47] 
NCT01159600
/ 
NCT01289990 
638 Empagliflozin 
vs placebo 
MET 55.7 57.0 White No No Renal failure  and acute renal 
failure based on prespecified 
SAE item from MedDRA  
Clinitrial trial 
registration 
76 
Kovacs CS 
(2014)[48] 
NCT01210001
/ 
NCT01289990 
499 Empagliflozin 
vs placebo 
PIOG+-MET 54.5 48.4 Asian No No Not reported3 Clinitrial trial 
registration 
76 
Rosenstock 
J (2014) 
[49] 
NCT01306214 563 Empagliflozin 
vs placebo 
INS 56.7 45.0 White No No Renal impairment and acute 
renal failure based on 
prespecified SAE item from 
MedDRA  
Clinitrial trial 
registration 
52 
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Rosenstock 
J (2015)[50]  
NCT01011868 494 Empagliflozin 
vs placebo 
INS ± OAD 58.8 55.9 White No No Renal failure and acute renal 
failure based on prespecified 
SAE item from MedDRA  
Clinitrial trial 
registration 
78 
Zinman B 
(2015)[51] 
NCT01131676 7020 Empagliflozin 
vs placebo 
Standard 
care 
63.2 71.0 White No Yes Incident or worsening 
nephropathy and acute renal 
impairment/failure based on 
prespecified AE items from 
MedDRA  
Publications 160 
NCT016492
97 
(2015)[52] 
NCT01649297 965 Empagliflozin 
vs placebo 
MET 58.2 53.9 NR No No Not reported3 Clinitrial trial 
registration 
16 
NCT017347
85 
(2016)[53] 
NCT01734785 332 Empagliflozin 
vs placebo 
LINA 55.2 59.6 NR No No Acute renal failure based on 
prespecified SAE item from 
MedDRA  
Clinitrial trial 
registration 
24 
NCT011932
18 
(2014)[54] 
NCT01193218 547 Empagliflozin 
vs placebo 
Naïve tre 
atment 
57.5 74.9 Asian No No Not reported3 Clinitrial trial 
registration 
12 
Tikkanen I 
(2015)[55] 
NCT01370005 823 Empagliflozin 
vs placebo 
OAD± INS 60.2 60.1 White No No Not reported3 Clinitrial trial 
registration 
12 
Roden M 
(2013)[56]  
NCT01177813
/ 
NCT01289990 
899 Empagliflozin 
vs SITA vs 
placebo 
Naïve 
treatment 
55 61.0 Asian  No No Acute renal failure based on 
prespecified SAE item from 
MedDRA 
Clinitrial trial 
registration 
76 
NCT007491
90 
(2014)[57] 
NCT00749190 495 Empagliflozin 
vs SITA vs 
placebo 
MET 58.3 49.5 White No No Not reported3 Clinitrial trial 
registration 
12 
Haneda M 
(2016)[58] 
JapicCTI-
111543 
145 Luseogliflozin 
vs placebo 
OAD 68 76.6 Asian Yes No AE related to renal function 
(e.g. blood  Cr increased and 
GFR decreased)  based on 
prespecified AE item from 
MedDRA  
Publications 24 
 
 
Abbreviation: NR,not reported; CKD, chronic kidney disease; GFR, glomerular filtration rate; EMPA, empagliflozin; DAPA, dapagliflozin; CANA, canagliflozin; PLA, placebo; MET, 
metformin; SIT, sitagliptin; SAXA, saxagliptin; LINA, linagliptin; SU, sulfonylureas; OAD, oral antidiabetic drugs; INS, insulin; PIOG, pioglitazone; MedDRA, medical dictionary for 
regulatory activities; AE, adverse event; SAE, serious adverse event; Cr, creatinine. 
1the data of these two trials presented on the clinicaltrials.gov together. 
2the report with two independent datasets for RCT, which were considered separately.  
3the incidence of adverse renal events was assumed to be zero 
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Figure S1 Risk of bias assessments 
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Table S3 Pairwise meta-analysis results of individual SGLT2 inhibitors on composite renal events 
Group/Subgroup n SGLT2 inhibitor 
(events/ 
patients) 
Control 
(events/ 
patients) 
Peto odds ratio 
 (95%CI) 
Heterogeneity 
(I2 %) 
Canagliflozin  
 Overall 15 62/7669 18/3678 1.69 (1.06, 2.72) 0 
Control Placebo 12 41/5114 15/2215 1.41 (0.80, 2.48) 0 
Other active treatments 4 21/2555 3/1463 2.57 (1.10, 6.04) 18.9 
Duration ≥ 104 weeks 2 12/1445 4/719 1.45 (0.51, 4.13) 0 
26-104 weeks 5 48/2626 14/1551 1.71 (1.00, 2.92)  37.8 
≤ 26 weeks 8 2/3598 0/1408 4.46 (0.23, 84.77) 0 
Mean 
age 
< 60 years 12 23/5731 3/2661 2.69 (1.18, 6.10) 0 
≥ 60 years 3 39/1939 15/1017 1.35 (0.76, 2.40) 0 
CVD Preexisting CVD 0 - - - - 
Non-preexisting CVD 15 62/7669 18/3678 1.69 (1.06, 2.72) 0 
CKD Preexisting CKD 1 17/179 8/90 1.07 (0.45, 2.57) - 
Non-preexisting CKD 14 45/7490 10/3588 2.05 (1.17, 3.59) 0 
Dapagliflozin 
 Overall 23 208/6528 97/6528 1.70 (1.34, 2.16) 11.1 
Control Placebo 20 184/5724 82/3299 1.71 (1.32, 2.21) 14.1 
Other active treatments 3 24/804 15/792 1.63 (0.86, 3.09) 37.9 
Duration ≥ 104 weeks 3 28/869 11/372 1.13 (0.56, 2.29) 0 
26-104 weeks 7 149/2250 70/1984 2.06 (1.56, 2.71) 0 
≤ 26 weeks 13 31/3409 16/1735 0.88 (0.47, 1.65) 12.9 
Mean 
age 
< 60 years 18 92/5219 40/2863 1.37 (0.95, 1.99) 5.3 
≥ 60 years 5 116/1309 57/1228 1.98 (1.45, 2.70) 7.6 
CVD Preexisting CVD 2 101/942 50/945 2.09 (1.50, 2.92) 0 
Non-preexisting CVD 21 107/5586 47/3146 1.37 (0.97, 1.92) 3.2 
CKD Preexisting CKD 2 16/342 9/171 0.88 (0.38, 2.07) 0 
Non-preexisting CKD 21 192/6186 88/3920 1.80 (1.40, 2.30) 9.8 
Empagliflozin 
 Overall 19 536/12783 399/6030 0.62 (0.54, 0.72) 33.3 
Control Placebo 14 535/10199 396/4585 0.62 (0.54, 0.72) 44.2 
Other active treatments 6 1/2584 3/1445 0.24 (0.03, 1.83) 8.7 
Duration ≥ 104 weeks 2 526/5452 389/3113 0.62 (0.53, 0.72) 0 
26-104 weeks 11 10/4593 9/2167 0.69 (0.27, 1.74) 51.9 
≤ 26 weeks 6 0/2738 1/750 0.05 (0.00, 3.15) - 
Mean 
age 
< 60 years 15 6/6852 6/3044 0.54 (0.17, 1.79) 49.3 
≥ 60 years 4 530/5931 393/2986 0.62 (0.54, 0.72) 0 
CVD Preexisting CVD 1 525/4687 388/2333 0.62 (0.53, 0.72) - 
Non-preexisting CVD 18 11/8096 11/3697 0.64 (0.27, 1.51) 41.6 
CKD Preexisting CKD 1 5/419 5/319 0.76 (0.21, 2.65) - 
Non-preexisting CKD 18 531/12364 394/5711 0.62 (0.53, 0.72) 41.1 
10 
 
Abbreviation: CI, confidence interval; CVD, cardiovascular disease; CKD, chronic kidney disease; -, not 
applicable   
Luseogliflozin 
 Placebo 1 8/95 6/50 0.67 (0.21, 2.11) - 
11 
 
 
Table S4 Assessment of loop inconsistency in networks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviation: CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; PLA, placebo; ACT, active 
treatments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Loop Inconsistency 
factor 
95% 
confidence 
interval 
P-value Loop 
heterogeneity 
tau2 
Composite renal events 
PLA-CANA-ACT 0.968 0.00-3.73 0.492 0.000 
PLA-EMPA-ACT 0.385 0.00-3.23 0.791 0.000 
PLA-DAPA-ACT 0.386 0.00-2.97 0.769 0.000 
Acute renal impairment/failure events 
PLA-DAPA-ACT 1.336 0.00-4.71 0.437 0.000 
PLA-EMPA-ACT 0.833 0.00-3.71 0.570 0.000 
PLA-CANA-ACT 0.774 0.00-4.07 0.645 0.000 
12 
 
 
Table S5 Assessment of global inconsistency in networks using the ‘design-by-treatment’ 
interaction model. 
 
 
Network outcome Chi square 
P value for test of global 
inconsistency 
Composite renal events 3.41 0.76 
Acute renal 
impairment/failure 3.65 0.72 
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Table S6 The results of the surface under the cumulative ranking curve (SUCRA) and mean ranks.  
. 
 Composite renal events Acute renal impairment/failure 
Treatment SUCRA MeanRank SUCRA MeanRank 
Placebo 52.1 3 30.7 4 
Canagliflozin  27.0 5 69.5 2 
Dapagliflozin  6.0 6 62.0 3 
Empagliflozin  90.0 1 72.9 1 
Luseogliflozin 74.6 2 - - 
Other Active 
treatments 
50.3 4 15.0 5 
Abbreviation: SUCRA, surface under the cumulative ranking curve 
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Table S7 Pairwise meta-analysis results of individual SGLT2 inhibitors on acute renal 
impairment/failure events 
 
Group/Subgroup n SGLT2 inhibitor 
(events/ 
patients) 
Control 
(events/ 
patients) 
Peto odds ratio 
 (95%CI) 
Heterogeneity 
(I2) 
Canagliflozin  
 Overall 14 4/5912 1/2751 1.82 (0.28, 11.77) 0 
Control Placebo 11 3/3832 1/1525 1.46 (0.18, 11.7) 0 
Other active treatments 4 1/2555 0/1463 4.47 (0.07, 286.7) - 
Duration ≥ 104 weeks 2 1/1445 0/719 4.47 (0.07, 286.7) - 
26-104 weeks 4 2/1344 1/861 1.01 (0.09, 11.17) - 
≤ 26 weeks 8 1/3598 0/1408 4.44 (0.07, 287.7) - 
Mean 
age 
< 60 years 12 2/5731 0/2661 4.45 (0.23, 84.77) 0 
≥ 60 years 2 2/656 1/327 1.01 (0.09, 11.17) - 
CVD Preexisting CVD 0 - - - - 
Non-preexisting CVD 14 4/5912 1/2751 1.82 (0.28, 11.8) 0 
CKD Preexisting CKD 1 2/179 1/90 1.01 (0.09, 11.17) - 
Non-preexisting CKD 13 2/6208 0/2898 4.45 (0.23, 84.77) 0 
Dapagliflozin 
 Overall 20 5/5760 2/3631 1.93 (0.42, 8.83) 39.8 
Control Placebo 17 4/5116 2/2999 1.52 (0.29, 7.92) 50.9 
Other active treatments 3 1/804 0/792 7.43 (0.15, 374.2) - 
Duration ≥ 104 weeks 3 0/869 1/372 0.05 (0.00, 3.18) - 
26-104 weeks 7 5/2250 1/1984 3.40 (0.66, 17.42) 6.6 
≤ 26 weeks 10 0/2801 0/1435 - - 
Mean 
age 
< 60 years 15 2/4611 0/2563 5.57 (0.29, 107.7) 0 
≥ 60 years 5 3/1309 2/1228 1.32 (0.22, 7.77) 66.2 
CVD Preexisting CVD 2 3/942 1/945 2.73 (0.38, 19.43) 66.8 
Non-preexisting CVD 18 2/4978 1/2846 1.14 (0.10, 12.7) 39.9 
CKD Preexisting CKD 2 0/342 1/171 0.05 (0.00, 3.18) - 
Non-preexisting CKD 18 5/5578 1/3620 3.40 (0.66, 17.42) 6.6 
Empagliflozin 
 Overall 19 298/12783 201/6030 0.72 (0.59, 0.87) 24.5 
Control Placebo 14 298/10199 198/4585 0.73 (0.60, 0.88) 24.9 
Other active treatments 6 0/2584 3/1445 0.07 (0.01, 0.74) 0 
Duration ≥ 104 weeks 2 291/5452 193/3113 0.73 (0.60, 0.88) 0 
26-104 weeks 11 7/4593 7/2167 0.58 (0.20, 1.74) 36.7 
≤ 26 weeks 6 0/2738 1/750 0.05 (0.00, 3.15) - 
Mean 
age 
< 60 years 15 4/6852 6/3044 0.33 (0.09, 1.22) 33.5 
≥ 60 years 4 294/5931 195/2986 0.73 (0.60, 0.89) 0 
CVD Preexisting CVD 1 291/4687 192/2333 0.73 (0.60, 0.89) - 
15 
 
 
Abbreviation: CI, confidence interval; CVD, cardiovascular disease; CKD, chronic kidney disease; -, not 
applicable 
 
 
 
 
Non-preexisting CVD 18 7/8096 9/3697 0.46 (0.17, 1.26) 28.2 
CKD Preexisting CKD 1 3/419 3/319 0.76 (0.15, 3.83) - 
Non-preexisting CKD 18 295/12364 198/5711 0.72 (0.59, 0.87) 32.9 
16 
 
Figure S2 Comparison-adjusted funnel plot for the network meta-analysis of SGLT2 inhibitors on 
composite renal events (A) and acute renal impairment/failure events (B). The red line represents the 
null hypothesis that the study-specific effect sizes do not differ from the respective comparison-specific 
pooled effect estimates. The two black dashed lines represent a 95% CI for the difference between study-
specific effect sizes and comparison-specific summary estimates. yixy is the noted effect size in study i that 
compares x with y. μxy is the comparison specific summary estimate for x versus y. 1, placebo; 2, 
canagliflozin; 3, dapagliflozin; 4, empagliflozin; 5, active treatments;6, luseogliflozin. 
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